<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infections due to &lt;i&gt;Serratia &lt;/i&gt;species</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infections due to <i>Serratia </i>species</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infections due to <i>Serratia </i>species</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebekah Moehring, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven Mahlen, PhD, D(ABMM)</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H26312050"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Serratia</em> species are gram-negative bacilli of the Enterobacterales order, although they are not a common component of healthy human fecal flora. In the early part of the 20<sup>th</sup> century, <em>Serratia marcescens</em> was considered a nonpathogenic organism and was used in medical experiments and as a biological warfare test agent [<a href="#rid1">1</a>]. Since the mid-1970s, however, <em>Serratia</em> species have been recognized to cause a full spectrum of human clinical disease. Additionally, <em>Serratia</em> species may harbor multidrug resistance mechanisms that can complicate treatment decisions.</p><p>This article will review the microbiology, epidemiology, clinical features, diagnosis, and treatment of infections caused by <em>Serratia </em>species. </p><p>Detailed discussion of particular infectious syndromes (eg, complicated urinary tract [UTI] infection or hospital-acquired pneumonia) that <em>Serratia</em> can cause can be found separately in topics dedicated to that syndrome:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis"</a> and  <a class="medical medical_review" href="/d/html/6913.html" rel="external">"Complications of contact lenses"</a> and  <a class="medical medical_review" href="/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1.html" rel="external">"Complications of abdominal surgical incisions", section on 'Surgical site infection'</a> and  <a class="medical medical_review" href="/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a> and  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/120681.html" rel="external">"Overview of the evaluation and management of surgical site infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2151.html" rel="external">"Native valve endocarditis: Epidemiology, risk factors, and microbiology"</a> and  <a class="medical medical_review" href="/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis"</a>.)</p><p></p><p class="headingAnchor" id="H26312057"><span class="h1">MICROBIOLOGY</span></p><p class="headingAnchor" id="H26312065"><span class="h2">Nomenclature</span><span class="headingEndMark"> — </span>The genus <em>Serratia</em> consists of at least 20 species, of which 8 are known to have caused infections in humans  (<a class="graphic graphic_table graphicRef90929" href="/d/graphic/90929.html" rel="external">table 1</a>) [<a href="#rid2">2</a>]. <em>S. marcescens</em> is the main human pathogen in the genus. Bartolomeo Bizio, a pharmacist, described an unusual red discoloration of polenta in 1819 in Padua, Italy after a particularly warm and humid summer [<a href="#rid1">1,3</a>]. He was able to cultivate the responsible organism and first named it <em>S. marcescens</em> in 1823 [<a href="#rid1">1,3</a>]. This organism has had a large number of other names in the literature, although only <em>Chromobacterium prodigiosum</em> was used commonly until the 1950s [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H250710438"><span class="h2">Characteristics</span><span class="headingEndMark"> — </span>The genus consists of facultatively anaerobic gram-negative rods  (<a class="graphic graphic_picture graphicRef90935" href="/d/graphic/90935.html" rel="external">picture 1</a>) in the order Enterobacterales that grow well on most commonly used laboratory media. Many strains of <em>S. marcescens</em>, <em>Serratia plymuthica</em>, and <em>Serratia rubidaea</em> are red-pigmented. However, the red pigment exhibited by <em>S. marcescens</em> is most commonly associated with environmental strains  (<a class="graphic graphic_picture graphicRef90934" href="/d/graphic/90934.html" rel="external">picture 2</a>). Because of this, the organism was used as a tracer organism in various medical and military experiments in the 1900s before human disease with this pathogen was fully appreciated [<a href="#rid1">1</a>]. Hospital-acquired strains are often not red-pigmented. Such colonies of <em>S. marcescens</em> are generally creamy white to grayish in color and grow well at standard incubator temperatures (35 to 37°C).</p><p>Automated bacterial identification systems and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) will reliably identify the more common <em>Serratia</em> species, including <em>S. marcescens</em>, <em>Serratia liquefaciens</em>, and <em>S. rubidaea. S. marcescens</em> produces the enzymes deoxyribonuclease (DNase), lipase, and gelatinase and is usually a lactose non-fermenter. The other, more uncommon, species may not be as easily identified because many commercial systems may not have evaluated them for inclusion in their databases, although MALDI-TOF technology can reliably identify the uncommon <em>Serratia</em> species. In general, however, the uncommon species, save <em>Serratia fonticola</em>, can at least be identified as belonging to the genus <em>Serratia</em> by DNase and gelatinase production [<a href="#rid1">1</a>]. In some cases, 16S ribosomal ribonucleic acid (rRNA) gene sequencing may be necessary to definitively determine identity, if clinically indicated.</p><p class="headingAnchor" id="H26312072"><span class="h2">Pathogenesis and virulence factors</span><span class="headingEndMark"> — </span><em>S. marcescens</em> and the other <em>Serratia</em> species do not produce many notable virulence factors and are considered opportunistic pathogens, although serious infections may occur in immunocompetent hosts [<a href="#rid1">1</a>]. <em>Serratia </em>species are motile and can adhere to cells via fimbriae. <em>S. marcescens</em> produces different exoproteins and compounds that may contribute to virulence [<a href="#rid1">1,4-7</a>].</p><p class="headingAnchor" id="H26312086"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1592593792"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The incidence of <em>Serratia</em> infections is estimated to be 10.8 per 100,000 people annually, with a hospital onset rate of 0.4 per 1000 inpatient discharges according to a single Canadian study [<a href="#rid8">8</a>]. In very preterm infants in a multicenter, United States study of 774 hospitals, the incidence of invasive <em>Serratia</em> was higher, around 2.3 <em>Serratia</em> infections per 1000 preterm infants [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H250710479"><span class="h2">Environmental reservoirs as the primary source of infection</span><span class="headingEndMark"> — </span>Human infections caused by <em>Serratia</em> species occur worldwide. They are thought to arise from exogenous environmental sources rather than from commensal flora. Since <em>S. marcescens</em> and the other <em>Serratia </em>species are commonly associated with the environment, they are particularly adept at causing nosocomial infections and hospital-associated outbreaks. </p><p>The various environmental niches for <em>Serratia</em> species, including <em>S. marcescens</em>, include  (<a class="graphic graphic_table graphicRef90929" href="/d/graphic/90929.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Water</p><p class="bulletIndent1"><span class="glyph">●</span>Soil</p><p class="bulletIndent1"><span class="glyph">●</span>Plants</p><p class="bulletIndent1"><span class="glyph">●</span>Animals</p><p class="bulletIndent1"><span class="glyph">●</span>Insects</p><p></p><p>While environmental <em>Serratia</em> species are sometimes associated with animals and insects, these organisms are not typically transmitted to humans through bites, scratches, or stings. Instead, <em>Serratia</em> species are usually acquired directly from contact with environmental sources. <em>Serratia</em> in the health care environment, specifically, may be related to the ability to form biofilms and resist biocides or disinfectants. Health care exposures may lead to gut colonization prior to invasive infections [<a href="#rid10">10,11</a>]. <em>Serratia</em> can be responsible for bacteremia and endocarditis in persons who inject drugs, likely also related to environmental contamination events [<a href="#rid12">12,13</a>]. </p><p class="headingAnchor" id="H26312093"><span class="h2">Hospital-onset infections</span><span class="headingEndMark"> — </span>Hospital-onset infections due to <em>Serratia</em> species are most commonly reported in association with outbreaks linked to an environmental or medical exposure, although they also occur outside the outbreak setting. <em>Serratia</em> species are encountered often enough to be included on most annual hospital antibiograms (&gt;30 isolates in a year). Clusters of <em>Serratia</em> infections occurring in the health care setting should be evaluated for a possible common source outbreak. </p><p class="headingAnchor" id="H250710509"><span class="h3">Outbreaks</span><span class="headingEndMark"> — </span>Over 200 reported hospital-based outbreaks caused by <em>S. marcescens</em> have been reported in the medical literature since 1950 [<a href="#rid1">1</a>]. Sources of reported outbreaks have included various environmental point sources (eg, tap water [<a href="#rid14">14</a>], disinfectant solutions [<a href="#rid15">15,16</a>], soap [<a href="#rid17">17,18</a>]) and therapeutic agents (eg, blood products [<a href="#rid19">19-21</a>], intravenous solutions [<a href="#rid22">22-26</a>]), as well as carriage and dissemination on health care worker hands [<a href="#rid27">27-29</a>]. Outbreaks have affected pediatric [<a href="#rid30">30</a>] and adult populations, immunocompromised hosts, intensive care units (ICUs) [<a href="#rid31">31,32</a>], and single hospitals as well as institutions across several states. </p><p>Some multistate outbreaks of <em>Serratia</em> bloodstream infections have gained national attention in the United States: </p><p class="bulletIndent1"><span class="glyph">●</span>In 2005, an <em>S. marcescens</em> bloodstream infection outbreak was linked to contaminated bags of intravenous <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> solution from a nationally distributing compounding pharmacy [<a href="#rid23">23</a>]. In total, the outbreak involved 18 patients in five states over a three-month period. All patient isolates had identical pulse-field gel electrophoresis profiles, as did isolates from unopened bags of magnesium sulfate from the same compounded lot.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A nine-state outbreak of 162 <em>S. marcescens</em> bloodstream infections from 2007 to 2008 was eventually linked to prefilled heparin and <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> syringes from a pharmaceutical manufacturer [<a href="#rid24">24,33</a>]. The US Food and Drug Administration (FDA) investigation concluded that inadequate compliance with regulatory standards was the likely reason for the contaminated products.</p><p></p><p>Patient risk factors identified in outbreaks due to <em>Serratia</em> have generally been consistent with other hospital-acquired infections and relate to high-risk health care exposures and impaired host immunity  (<a class="graphic graphic_table graphicRef90930" href="/d/graphic/90930.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H250710503"><span class="h3">Individual infections</span><span class="headingEndMark"> — </span>Hospital onset infections due to <em>Serratia</em> may also infrequently occur outside of an outbreak scenario. Surveillance reports from European ICUs list <em>Serratia</em> as the primary pathogen in 3.4 percent of bloodstream infections and 5.3 percent of pneumonias [<a href="#rid34">34</a>]. Similarly low percentages are reported in hospitalized patients in North and Latin America: 1.6 percent of bloodstream infections [<a href="#rid35">35</a>] and 2 to 4 percent of pneumonias [<a href="#rid36">36</a>]. A Japanese survey reported 6.8 percent of all urinary tract infections (UTIs) were caused by <em>Serratia</em> species [<a href="#rid37">37</a>]. </p><p>The presence of an invasive device is an important risk factor for hospital-acquired <em>Serratia</em> infections. However, surveillance data suggest that <em>Serratia</em> is not a predominant device-related infection pathogen in the United States. Although it was previously one of the top 10 pathogens encountered in health care-associated infections, surveillance data from 2015 to 2017 showed that <em>Serratia</em> declined in frequency in the United States and ranked <em>Serratia</em> species below the top 10 for cause of central line-associated bloodstream infections and catheter-associated UTI. For ventilator-associated pneumonia, it was ranked eighth (4.6 percent) among patients in intensive care units and sixth (5.0 percent) among patients in long-term acute care facilities [<a href="#rid38">38</a>]. <em>Serratia</em> was also an infrequent cause of surgical site infections following abdominal (0.4 percent of infections), cardiac (5.5 percent), orthopedic (1.8 percent), and obstetric/gynecologic (1.1 percent) procedures [<a href="#rid38">38</a>]. <em>Serratia</em> is intrinsically resistant to <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>, the most commonly used surgical prophylaxis agent. Thus, clusters of <em>Serratia</em> infections occurring in the health care setting should be evaluated for a possible common source outbreak [<a href="#rid30">30</a>]. (See <a class="local">'Outbreaks'</a> above.)</p><p>Preterm infants cared for in neonatal ICUs may be at particular risk for <em>Serratia</em> late-onset bloodstream and central nervous system (CNS) infections. In an observational study from 2018 to 2020 that included &gt;100,000 preterm and low birthweight infants at 774 hospitals in the United States, 279 had <em>Serratia</em> infection [<a href="#rid9">9</a>]. Infants with <em>Serratia</em> infection had higher rates of tracheostomy, gastrostomy, and home oxygen use compared with infants with other infections. Rates of <em>Serratia</em> infection were higher in academic hospitals with large neonatal ICUs that offered complex medical and surgical services.</p><p class="headingAnchor" id="H26312100"><span class="h2">Community-onset infections</span><span class="headingEndMark"> — </span>The extent of the role of <em>Serratia</em> species in community-onset infections is not well delineated. In a population-based, laboratory surveillance study in Canada, 65 percent of incident <em>Serratia</em> isolates were associated with community-onset infections [<a href="#rid8">8</a>]. However, this study was not able to distinguish between health care-associated infections that were identified in the community and true community-acquired infections. Nevertheless, community-based environmental reservoirs of <em>Serratia</em> species may play a larger role than previously appreciated, as the literature on <em>Serratia</em> is dominated by reports of outbreaks likely related to a common environmental reservoir and infections following particular environmental exposures [<a href="#rid1">1,14,29,33</a>]. Comparable studies investigating <em>Serratia</em> in patient populations outside health care settings are needed to better define its prevalence.</p><p class="headingAnchor" id="H26312107"><span class="h1">DISEASE ASSOCIATIONS</span><span class="headingEndMark"> — </span><em>Serratia</em> species have been isolated from a variety of clinical specimens  (<a class="graphic graphic_table graphicRef90929" href="/d/graphic/90929.html" rel="external">table 1</a>). <em>Serratia</em> species are not, however, the dominant pathogens for any particular clinical syndrome, except for ocular infections. The mechanism of inoculation and the source of the pathogen often remain unknown. Infections due to <em>Serratia</em> species have clinical manifestations similar to infections caused by other bacterial pathogens. Clinical manifestations of particular infectious syndromes (eg, complicated urinary tract infection [UTI] or hospital-acquired pneumonia) are discussed separately in topics dedicated to that syndrome.</p><p><em>S. marcescens</em> is an established human pathogen associated with UTI, pneumonia, and bloodstream infection [<a href="#rid35">35-37,39,40</a>]. Endocarditis caused by <em>Serratia</em> species has been described, especially among persons who inject drugs [<a href="#rid41">41-43</a>].</p><p>Skin and soft tissue infections, including various wound infections, surgical site infections [<a href="#rid29">29-31,44-46</a>], and even necrotizing fasciitis [<a href="#rid47">47-49</a>] are infrequently encountered, as well as osteomyelitis and septic arthritis [<a href="#rid42">42</a>]. </p><p>Central nervous system (CNS) infections due to <em>Serratia</em> are often linked with prior instrumentation such as ventriculoperitoneal shunts and other surgeries, lumbar puncture [<a href="#rid50">50</a>], or spinal injections [<a href="#rid51">51-53</a>]. Meningoencephalitis has been described in neonates [<a href="#rid9">9,54,55</a>].</p><p><em>Serratia</em> species cause a larger proportion of infections of the eye than other infections, and in some studies, they are one of the most commonly isolated pathogens, along with <em>Pseudomonas aeruginosa</em>, among hospital-acquired or contact lens-associated ocular infections [<a href="#rid56">56,57</a>]. These include conjunctivitis, keratoconjunctivitis [<a href="#rid58">58</a>], corneal ulcers, and keratitis [<a href="#rid59">59</a>]. Endophthalmitis caused by <em>Serratia</em> is rare, but long-term outcomes can be severe. In one case series of 10 patients with endophthalmitis caused by <em>S. marcescens</em>, 60 percent experienced complete vision loss [<a href="#rid60">60</a>]. Case series of nosocomial eye infections have been mainly described in neonates and children, post-traumatic ocular infections, and in persons who wear contact lenses [<a href="#rid1">1,59,61</a>]. </p><p class="headingAnchor" id="H26312114"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Infection with <em>Serratia</em> species cannot be distinguished from other bacterial pathogens that cause similar infectious syndromes on the basis of signs and symptoms alone. Thus, the diagnosis of <em>Serratia</em> infection is confirmed by identification of the organism on culture of the relevant clinical specimen (eg, blood, sputum, urine, or aspirated body fluid). If endophthalmitis is suspected, vitreous cultures should be collected for diagnosis and susceptibility testing; blood cultures should also be collected to evaluate if the mechanism was hematogenous seeding. Details on diagnosis of particular infectious syndromes (eg, complicated urinary tract [UTI] infection or hospital-acquired pneumonia) are discussed separately in topics dedicated to those syndromes.</p><p>Since <em>Serratia</em> species are commonly found in the environment, the clinical presentation should always be taken into account when evaluating recovery of these organisms from clinical specimens in order to distinguish infection from contamination or colonization. For example, pseudo-outbreaks of <em>Serratia</em> due to contaminated specimen tubes during blood culture collection or due to contaminated bronchoscopes have been described [<a href="#rid62">62,63</a>]. </p><p>Automated bacterial identification systems and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) will reliably identify the more common <em>Serratia</em> species, including <em>S. marcescens</em>, <em>S. liquefaciens</em>, and <em>S. rubidaea.</em> In some cases, 16S ribosomal ribonucleic acid (rRNA) gene sequencing may be necessary to definitively determine identity if clinically indicated, but the species detail is generally not necessary for making treatment decisions. </p><p>Antibiotic susceptibility testing guidelines are well established for <em>Serratia</em> species, particularly <em>S. marcescens</em>, and standard sensitivities can be determined using most automated systems [<a href="#rid64">64,65</a>]. Interpretation of susceptibility results, however, requires a nuanced approach due to known mechanisms of antibiotic resistance. (See <a class="local">'Antimicrobial resistance'</a> below.)</p><p class="headingAnchor" id="H340695420"><span class="h1">ANTIMICROBIAL RESISTANCE</span><span class="headingEndMark"> — </span>In addition to intrinsic resistance to various antibiotics, <em>Serratia</em> species can also have broad-spectrum beta-lactam resistance through production of AmpC beta-lactamase, extended-spectrum beta-lactamases (ESBLs), and carbapenemases.</p><p class="headingAnchor" id="H2664656696"><span class="h2">Intrinsic resistance</span><span class="headingEndMark"> — </span><em>Serratia </em>species are intrinsically resistant to <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, narrow-spectrum cephalosporins (including <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>), cephamycins, <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a>, macrolides, <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a>, and <a class="drug drug_general" data-topicid="9704" href="/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a>, and polymyxins [<a href="#rid64">64-66</a>]. </p><p class="headingAnchor" id="H340695467"><span class="h2">AmpC beta-lactamase</span><span class="headingEndMark"> — </span><em>S. marcescens</em> and several other <em>Serratia</em> species encode an inducible, chromosomal AmpC beta-lactamase, although it is typically expressed at low levels [<a href="#rid67">67</a>]. In contrast to other Enterobacterales (eg, <em>Klebsiella aerogenes</em>, <em>Citrobacter freundii</em>, <em>Enterobacter cloacae</em>) that are at moderate to high risk of ampC induction, <em>Serratia</em> is considered to be at lower risk of expressing AmpC (&lt;5 percent of isolates) [<a href="#rid68">68</a>]. At the low levels at which this enzyme is typically expressed, AmpC beta-lactamase mediates resistance to several beta-lactam antibiotics, such as penicillins and first-generation cephalosporins, but resistance to later-generation cephalosporins may not be detected on initial antibiotic susceptibility tests. In the laboratory, the best method to screen for AmpC production is to monitor for <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a> or <a class="drug drug_general" data-topicid="9222" href="/d/drug information/9222.html" rel="external">cefotetan</a> resistance since organisms that produce AmpC are intrinsically resistant to cephamycins.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inducible AmpC</strong> – Exposure to certain beta-lactams can lead to transcriptional induction and transiently increased expression of AmpC beta-lactamase. However, this induction may not be clinically relevant, because most isolates do not have mutations that result in stable expression of high levels of AmpC, and they express only low levels of AmpC when they first encounter antibiotics. For example, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> is a potent inducer of AmpC, but induction by imipenem does not result in resistance to imipenem or other carbapenems [<a href="#rid69">69</a>]. Third-generation cephalosporins such as <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, and <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> are weak inducers, and induction may result in a relatively small increase in minimum inhibitory concentration to these agents. If enough AmpC beta-lactamase is produced, this may result in hydrolysis of third-generation cephalosporins, but there is no evidence to suggest this induction is clinically relevant [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Derepressed AmpC and plasmid-mediated AmpC</strong> – Derepressed mutants, in contrast to the “induced”<em> </em>example above, are isolates that have pre-existing, constitutive mutations that ensure high levels of AmpC even in the absence of antibiotic pressure. These mutations generally result in higher levels of AmpC than simple induction, and the resistant isolate emerges from mixed populations quickly after exposure to antibiotics. Treatment with third-generation cephalosporins such as <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> can select for derepressed mutants that cause rapidly emerging resistance and treatment failures. In addition, plasmid-mediated AmpC beta-lactamases that are usually produced at high levels have also been found in some <em>S. marcescens</em> strains. </p><p></p><p class="bulletIndent1">Both derepressed mutants and plasmid-mediated AmpC producers are resistant to all beta-lactams except carbapenems and perhaps <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> [<a href="#rid67">67,70</a>]. The cephalosporin plus beta-lactamase inhibitor combination <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>/avibactam has in vitro activity against AmpC-producing organisms including<em> Serratia</em> species; ceftazidime/avibactam maintains in vitro susceptibility even for ceftazidime non-susceptible isolates [<a href="#rid71">71</a>]. However, clinical data on use of these agents for such infections are limited [<a href="#rid72">72</a>].</p><p></p><p class="headingAnchor" id="H340695518"><span class="h2">Extended-spectrum beta-lactamase (ESBL)</span><span class="headingEndMark"> — </span><em>S. marcescens</em> is also known to produce ESBLs, which are plasmid encoded. The prevalence of ESBLs in <em>S. marcescens</em> has not been determined on a large scale in the United States; studies from other countries indicate a large variance in prevalence. As an example, in a study from two hospitals in Poland 19 percent of <em>S. marcescens</em> isolates from 1996 to 2000 were ESBL producers [<a href="#rid73">73</a>]. In contrast, in a separate study from Poland, 70.8 percent of <em>S. marcescens</em> isolates from 2003 to 2004 produced ESBLs [<a href="#rid74">74</a>]. Resistance to third-generation cephalosporins such as <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is the best indication of the presence of an ESBL in a <em>Serratia</em> isolate, although AmpC beta-lactamase expressed at high levels could also mediate resistance to these antibiotics. There are approved ESBL-confirmatory tests for <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, <em>Klebsiella oxytoca</em>, and <em>Proteus mirabilis</em>, but these are not recommended for <em>S. marcescens </em>[<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases"</a>.)</p><p class="headingAnchor" id="H42051033"><span class="h2">Carbapenemase</span><span class="headingEndMark"> — </span>Some strains of <em>S. marcescens</em> encode chromosomal carbapenemases (the SME family of enzymes) that mediate resistance to penicillins, first-generation cephalosporins, carbapenems (particularly <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>), and <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a> [<a href="#rid76">76</a>]. In addition, some <em>S. marcescens</em> strains have been found to harbor plasmid-mediated carbapenemases such as KPC-2, OXA-48, IMP, VIM, and NDM-1, which can strongly hydrolyze carbapenems if produced at high levels [<a href="#rid76">76-79</a>]. (See  <a class="medical medical_review" href="/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)"</a>.)</p><p class="headingAnchor" id="H26312136"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span><em>Serratia</em> species are generally susceptible to several antibiotic classes: fluoroquinolones, aminoglycosides, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, third- and fourth-generation cephalosporins, <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>, and carbapenems [<a href="#rid80">80</a>]. Antibiotic choice depends on the site of infection and the ability of the chosen drug to penetrate into the infected areas, susceptibility testing results, and the likelihood of emerging drug resistance during a treatment course. Institutional antibiogram data should be used to select empiric therapy while awaiting susceptibility information. Typically, either <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> or <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>/tazobactam is used.</p><p>Clinical trial data that include patients with <em>Serratia</em> infections in order to evaluate the comparable efficacy of various antibiotic agents are limited. A trial comparing <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> with <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> among 72 patients with bloodstream infection caused by Enterobacterales that produced chromosomal AmpC found no clear difference in overall clinical and microbiologic outcomes; piperacillin-tazobactam resulted in a higher microbiologic failure rate (13 versus 0 percent) but a lower microbiologic relapse rate (0 versus 9 percent, a difference that was not statistically significant) [<a href="#rid81">81</a>]. However, the study size may not have been large enough to detect an overall difference, and there was an imbalance of cointerventions between the two arms that limits interpretation of the findings. Furthermore, only 25 patients with <em>Serratia</em> infection were included, so the trial does not clearly inform optimal antibiotic choice for <em>Serratia</em>. Observational data also suggest no difference in mortality outcomes based on treatment choice, but definitive conclusions are difficult given confounding biases [<a href="#rid82">82-84</a>].</p><p>As with any bacterial infection, adequate control of the source of the infection is critical and may include removal of invasive devices and prosthetic material, drainage of abscess, and adequate debridement of infected tissues and bone. Details on other management issues beyond systemic antibiotic choice for particular infectious syndromes (eg, complicated urinary tract infection [UTI], bacteremia, or hospital-acquired pneumonia) are discussed separately in topics dedicated to that syndrome.</p><p class="headingAnchor" id="H250711684"><span class="h2">Susceptible isolates</span><span class="headingEndMark"> — </span>In cases of infection caused by isolates that do not have substantial drug resistance, the selection of antibiotics depends on the risk of emergent resistance during treatment, which in turn depends on the site of infection, the initial inoculum, and the presence of retained infected material, as well as the expected duration of therapy and the potential toxicity of treatment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uncomplicated infections/sites with good drug penetration</strong> – For uncomplicated infections in sites with good drug penetration, such as UTIs, minor skin and soft tissue infections, and pneumonia, fluoroquinolones, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, third- and fourth-generation cephalosporins, and carbapenems are all appropriate options if the isolate in question is susceptible. Aminoglycosides are generally used as monotherapy only for lower UTIs. (See  <a class="medical medical_review" href="/d/html/483.html" rel="external">"Aminoglycosides", section on 'Clinical use'</a>.) </p><p></p><p class="bulletIndent1">For uncomplicated bacteremia due to<em> Serratia</em>, a reasonable approach is to transition from an intravenous regimen chosen empirically based on the local antibiogram to a highly bioavailable oral agent to which the isolate is susceptible to complete the treatment course. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Duration and route of therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe infections in sequestered sites/infections that warrant long treatment courses</strong> – For more severe infections in sequestered sites with impaired drug penetration or high pathogen inoculum and for infections that require long treatment courses, antibiotic selection takes into consideration the potential for emergent AmpC-beta-lactamase-mediated resistance to third-generation cephalosporins that may not be evident during initial susceptibility testing [<a href="#rid75">75</a>]. (See <a class="local">'AmpC beta-lactamase'</a> above.) </p><p></p><p class="bulletIndent1">We consider central nervous system (CNS) infections, infections in sequestered sites (eg, endocarditis or osteomyelitis), and cases in which adequate debridement of infected material cannot be performed or infected prosthetic material cannot be removed to be higher-risk situations for emergence of AmpC-mediated resistance. In these situations, we suggest against using third-generation cephalosporins (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>) even if the isolate tests susceptible. This recommendation is based on limited, small studies that report clinical failure in a small proportion of patients [<a href="#rid85">85-89</a>]. </p><p></p><p class="bulletIndent1">For CNS infections, we favor the use of a carbapenem (<a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>) or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>. If cefepime is used, high dosing (2 g every 8 hours) or extended infusions should be used to ensure adequate penetration of the infected area. (See  <a class="medical medical_review" href="/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1">For other infections in sequestered sites, transition to oral fluoroquinolones or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> is likely appropriate to complete the treatment course, if the isolate is susceptible. </p><p></p><p>No large studies describe a significant risk of clinical failure with <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> therapy for <em>Serratia</em> infections if susceptibility has been proven in vitro [<a href="#rid85">85</a>]. <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">Piperacillin</a> may be less selective for AmpC derepressed mutants than some cephalosporins, and tazobactam has some beta-lactamase inhibitory activity against AmpC. Some microbiology laboratories may suppress reporting of cephalosporin and beta-lactam/beta-lactamase inhibitor susceptibility tests in order to discourage their use for species at risk of AmpC expression.</p><p>For suspected endophthalmitis due to <em>Serratia</em> species, ophthalmology consultation is recommended. Intravitreal antibiotic administration is necessary for treatment of endophthalmitis, typically with <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> or an aminoglycoside. Such patients may require vitrectomy if presentation is severe or vitreous cultures do not clear. (See  <a class="medical medical_review" href="/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a>.)</p><p>Topical agents appropriate for less severe ocular infections such as keratitis include fluoroquinolones or aminoglycosides.</p><p class="headingAnchor" id="H250710409"><span class="h2">Multidrug-resistant isolates</span><span class="headingEndMark"> — </span>Antibiotic options for multidrug-resistant isolates, either due to high-level expression of AmpC beta-lactamase or an extended-spectrum beta-lactamase (ESBL), are limited, regardless of the site of infection. A carbapenem (<a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a>) is generally the treatment of choice for most multidrug-resistant isolates. </p><p>For isolates that express high levels of AmpC beta-lactamase, the only reliable agents from the beta-lactam class are the carbapenems (see <a class="local">'AmpC beta-lactamase'</a> above). Data suggest <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> can potentially be effective, but its role in therapy of infections due to stably derepressed mutants producing AmpC beta-lactamase has not yet been fully defined. In a study of 96 patients with infections due to laboratory-confirmed AmpC beta-lactamase-producing organisms (13 of which were <em>Serratia</em> species), 96 percent of the isolates were susceptible to cefepime [<a href="#rid82">82</a>]. There was no difference in 30-day mortality associated with treatment with cefepime versus <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>. </p><p>Agents from other classes (eg, fluoroquinolones) can still be used despite production of AmpC beta-lactamase if the isolate tests susceptible and the agent is appropriate for the site of infection.</p><p>For infections with <em>Serratia</em> species that produce an ESBL, carbapenems remain the drugs of choice. Treatment of infections caused by ESBL-producing organisms is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/469.html" rel="external">"Extended-spectrum beta-lactamases", section on 'Treatment options'</a>.)</p><p>In the case that carbapenems cannot be used for multidrug-resistant <em>Serratia</em> species because of patient intolerance or carbapenem resistance, antibiotic selection should be made in consultation with an expert in treating drug-resistant infections.</p><p>There are several agents targeting multidrug-resistant gram-negative organisms, particularly carbapenem-resistant Enterobacteriaceae: <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="114672" href="/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>, imipenem-relebactam, <a class="drug drug_general" data-topicid="118322" href="/d/drug information/118322.html" rel="external">plazomicin</a>, <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a>, and <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>. Appropriate use of these agents depends on the mechanism of resistance, source of infection, risk of toxicity, and availability of resistance testing. For example, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>/avibactam is effective against some carbapenemases (KPC) but not others (NDM-1). (See  <a class="medical medical_review" href="/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftolozane-tazobactam'</a> and  <a class="medical medical_review" href="/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftazidime-avibactam'</a>.)</p><p class="headingAnchor" id="H250711440"><span class="h2">Monitoring</span><span class="headingEndMark"> — </span>Patients with <em>Serratia</em> infections should be monitored for clinical response during treatment. For cases in which the patient is not clinically improving on cephalosporin therapy or in which cultures are repeatedly positive, susceptibility testing should be repeated and therapy adjusted accordingly. Emergence of AmpC-derepressed mutants may be seen in as early as three to four days [<a href="#rid75">75</a>]. (See <a class="local">'AmpC beta-lactamase'</a> above.) </p><p class="headingAnchor" id="H250711319"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>Duration of therapy depends on the site of infection and the patient's clinical response. Infection with <em>Serratia</em> species does not warrant a longer course of therapy than generally indicated for the type of infection. Duration of therapy for particular infectious syndromes (eg, complicated UTI or hospital-acquired pneumonia) is discussed separately in topics dedicated to that syndrome.</p><p class="headingAnchor" id="H26312143"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – <em>Serratia marcescens</em> is the main human pathogen in the genus, which consists of facultatively anaerobic gram-negative rods in the order Enterobacterales that grow well on most commonly used laboratory media. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong><em>S. marcescens</em> and the other species are widely present in the environment and thus are associated in particular with hospital-onset infections and hospital-associated outbreaks. Clusters of infections due to <em>Serratia</em> that occur in hospitalized patients should trigger evaluation for a potential common source outbreak. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Hospital-onset infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of </strong><strong><em>Serratia</em></strong><strong> infections </strong>–<strong> </strong><em>Serratia</em> species can cause a wide spectrum of human infections that involve the urinary tract, bloodstream, skin and soft tissue, bone, respiratory tract, central nervous system (CNS), and eye. However, infections due to <em>Serratia</em> species are relatively infrequent compared to other pathogens for these syndromes, except for eye infections. (See <a class="local">'Disease associations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial resistance patterns </strong>–<strong> </strong><em>Serratia</em> species are intrinsically resistant to <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>, <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>, <a class="drug drug_general" data-topicid="8745" href="/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a>, narrow-spectrum cephalosporins, cephamycins, <a class="drug drug_general" data-topicid="9230" href="/d/drug information/9230.html" rel="external">cefuroxime</a>, macrolides, tetracyclines, <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a>, <a class="drug drug_general" data-topicid="9704" href="/d/drug information/9704.html" rel="external">nitrofurantoin</a>, and the polymyxins. Additionally, <em>Serratia</em> species have the potential to harbor multidrug resistance mechanisms (such as AmpC or extended-spectrum beta-lactamases and carbapenemases) and to develop resistance to broad-spectrum beta-lactams during therapy. (See <a class="local">'Antimicrobial resistance'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial selection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uncomplicated infections</strong> – For uncomplicated infections in sites with good drug penetration, such as urinary tract infections (UTIs), minor skin and soft tissue infections, uncomplicated bacteremia, and pneumonia, fluoroquinolones, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, third- and fourth-generation cephalosporins, and carbapenems are all appropriate options for treatment if the isolate in question is susceptible. Aminoglycosides are generally used as monotherapy only for lower UTIs. (See <a class="local">'Susceptible isolates'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe or complicated infections</strong> – The risk of emergence of AmpC-mediated resistance during therapy is likely higher with CNS infections, infections in sequestered sites that require prolonged antibiotic therapy, and cases in which infected material cannot be removed or adequately debrided. For patients with such infections, we suggest <strong>not</strong> using a third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>) even if the isolate tests susceptible (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Instead, for CNS infections, we favor the use of a carbapenem (<a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>) or <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>. For other infections in sequestered sites, fluoroquinolones and <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> are likely appropriate. (See <a class="local">'Susceptible isolates'</a> above.)</p><p></p><p class="bulletIndent2">High-level expression of AmpC beta-lactamase or an extended-spectrum beta-lactamase further limits treatment options, generally the carbapenem class is the primary option. However, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> and agents outside the beta-lactam class may still be effective in isolates that produce AmpC if testing demonstrated susceptibility to those agents. (See <a class="local">'Multidrug-resistant isolates'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antimicrobial duration and adjustment </strong>–<strong> </strong>Duration of therapy depends on the site of infection and the patient's clinical response. Culture and susceptibility testing should be repeated and therapy adjusted accordingly for patients who do not clinically improve on cephalosporin therapy because of the potential to select for AmpC beta-lactamase-producing isolates. (See <a class="local">'Monitoring'</a> above and <a class="local">'Duration of therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mahlen SD. Serratia infections: from military experiments to current practice. Clin Microbiol Rev 2011; 24:755.</a></li><li class="breakAll">Genus Serratia. List of Prokaryotic names with Standing in Nomenclature. http://www.bacterio.net/serratia.html (Accessed on July 31, 2016).</li><li><a class="nounderline abstract_t">Bizio B. Lettera di Bartolomeo Bizio al Chiarissimo canonico Angelo Bellani sopra il fenomeno della polenta porporina. Bibl Ital G Lett Sci Art 1823; VIII:275.</a></li><li><a class="nounderline abstract_t">Weakland DR, Smith SN, Bell B, et al. The Serratia marcescens Siderophore Serratiochelin Is Necessary for Full Virulence during Bloodstream Infection. Infect Immun 2020; 88.</a></li><li><a class="nounderline abstract_t">Di Venanzio G, Stepanenko TM, García Véscovi E. Serratia marcescens ShlA pore-forming toxin is responsible for early induction of autophagy in host cells and is transcriptionally regulated by RcsB. Infect Immun 2014; 82:3542.</a></li><li><a class="nounderline abstract_t">Lin CS, Horng JT, Yang CH, et al. RssAB-FlhDC-ShlBA as a major pathogenesis pathway in Serratia marcescens. Infect Immun 2010; 78:4870.</a></li><li><a class="nounderline abstract_t">Stella NA, Callaghan JD, Zhang L, et al. SlpE is a calcium-dependent cytotoxic metalloprotease associated with clinical isolates of Serratia marcescens. Res Microbiol 2017; 168:567.</a></li><li><a class="nounderline abstract_t">Laupland KB, Parkins MD, Gregson DB, et al. Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region. Eur J Clin Microbiol Infect Dis 2008; 27:89.</a></li><li><a class="nounderline abstract_t">Coggins SA, Edwards EM, Flannery DD, et al. Serratia Infection Epidemiology Among Very Preterm Infants in the Neonatal Intensive Care Unit. Pediatr Infect Dis J 2023; 42:152.</a></li><li><a class="nounderline abstract_t">Rao K, Seekatz A, Bassis C, et al. Enterobacterales Infection after Intestinal Dominance in Hospitalized Patients. mSphere 2020; 5.</a></li><li><a class="nounderline abstract_t">Moles L, Gómez M, Moroder E, et al. Serratia marcescens colonization in preterm neonates during their neonatal intensive care unit stay. Antimicrob Resist Infect Control 2019; 8:135.</a></li><li><a class="nounderline abstract_t">Phadke VK, Jacob JT. Marvelous but Morbid: Infective endocarditis due to Serratia marcescens. Infect Dis Clin Pract (Baltim Md) 2016; 24:143.</a></li><li><a class="nounderline abstract_t">Shah S, Clarke LG, Shields RK. Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis. Open Forum Infect Dis 2023; 10:ofad052.</a></li><li><a class="nounderline abstract_t">Horcajada JP, Martínez JA, Alcón A, et al. Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication. Infect Control Hosp Epidemiol 2006; 27:774.</a></li><li><a class="nounderline abstract_t">Ehrenkranz NJ, Bolyard EA, Wiener M, Cleary TJ. Antibiotic-sensitive Serratia marcescens infections complicating cardiopulmonary operations: contaminated disinfectant as a reservoir. Lancet 1980; 2:1289.</a></li><li><a class="nounderline abstract_t">de Frutos M, López-Urrutia L, Domínguez-Gil M, et al. Serratia marcescens outbreak due to contaminated 2% aqueous chlorhexidine. Enferm Infecc Microbiol Clin 2017; 35:624.</a></li><li><a class="nounderline abstract_t">Archibald LK, Corl A, Shah B, et al. Serratia marcescens outbreak associated with extrinsic contamination of 1% chlorxylenol soap. Infect Control Hosp Epidemiol 1997; 18:704.</a></li><li><a class="nounderline abstract_t">Buffet-Bataillon S, Rabier V, Bétrémieux P, et al. Outbreak of Serratia marcescens in a neonatal intensive care unit: contaminated unmedicated liquid soap and risk factors. J Hosp Infect 2009; 72:17.</a></li><li><a class="nounderline abstract_t">Boulton FE, Chapman ST, Walsh TH. Fatal reaction to transfusion of red-cell concentrate contaminated with Serratia liquefaciens. Transfus Med 1998; 8:15.</a></li><li><a class="nounderline abstract_t">Duncan KL, Ransley J, Elterman M. Transfusion-transmitted Serratia liquifaciens from an autologous blood unit. Transfusion 1994; 34:738.</a></li><li><a class="nounderline abstract_t">Ramírez-Arcos S, Chin-Yee I, Hume H, et al. Fatal septic shock associated with transfusion-transmitted Serratia marcescens. Transfusion 2006; 46:679.</a></li><li><a class="nounderline abstract_t">Bennett SN, McNeil MM, Bland LA, et al. Postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995; 333:147.</a></li><li><a class="nounderline abstract_t">Sunenshine RH, Tan ET, Terashita DM, et al. A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy. Clin Infect Dis 2007; 45:527.</a></li><li><a class="nounderline abstract_t">Blossom D, Noble-Wang J, Su J, et al. Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes. Arch Intern Med 2009; 169:1705.</a></li><li><a class="nounderline abstract_t">Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of Serratia marcescens associated with the anesthetic agent propofol. Am J Infect Control 2001; 29:312.</a></li><li><a class="nounderline abstract_t">Gupta N, Hocevar SN, Moulton-Meissner HA, et al. Outbreak of Serratia marcescens bloodstream infections in patients receiving parenteral nutrition prepared by a compounding pharmacy. Clin Infect Dis 2014; 59:1.</a></li><li><a class="nounderline abstract_t">de Vries JJ, Baas WH, van der Ploeg K, et al. Outbreak of Serratia marcescens colonization and infection traced to a healthcare worker with long-term carriage on the hands. Infect Control Hosp Epidemiol 2006; 27:1153.</a></li><li><a class="nounderline abstract_t">Hejazi A, Aucken HM, Falkiner FR. Epidemiology and susceptibility of serratia marcescens in a large general hospital over an 8-year period. J Hosp Infect 2000; 45:42.</a></li><li><a class="nounderline abstract_t">Passaro DJ, Waring L, Armstrong R, et al. Postoperative Serratia marcescens wound infections traced to an out-of-hospital source. J Infect Dis 1997; 175:992.</a></li><li><a class="nounderline abstract_t">Voelz A, Müller A, Gillen J, et al. Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management. Int J Hyg Environ Health 2010; 213:79.</a></li><li><a class="nounderline abstract_t">de Boer MG, Brunsveld-Reinders AH, Salomons EM, et al. Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics. J Infect 2008; 56:446.</a></li><li><a class="nounderline abstract_t">van der Sar-van der Brugge S, Arend SM, Bernards AT, et al. Risk factors for acquisition of Serratia marcescens in a surgical intensive care unit. J Hosp Infect 1999; 41:291.</a></li><li><a class="nounderline abstract_t">Sikka MK, Hayden MK, Pur S, et al. Microbiologic and clinical epidemiologic characteristics of the Chicago subset of a multistate outbreak of Serratia marcescens bacteremia. Infect Control Hosp Epidemiol 2010; 31:1191.</a></li><li class="breakAll">European Centre for Disease Prevention and Control. Healthcare-associated infections acquired in intensive care units: Annual Epidemiological Report for 2017. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-HAI.pdf (Accessed on September 17, 2020).</li><li><a class="nounderline abstract_t">Diekema DJ, Pfaller MA, Jones RN, et al. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents 2000; 13:257.</a></li><li><a class="nounderline abstract_t">Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51 Suppl 1:S81.</a></li><li><a class="nounderline abstract_t">Ishikawa K, Matsumoto T, Yasuda M, et al. The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy. J Infect Chemother 2011; 17:126.</a></li><li><a class="nounderline abstract_t">Weiner-Lastinger LM, Abner S, Edwards JR, et al. Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 2020; 41:1.</a></li><li><a class="nounderline abstract_t">LANCASTER LJ. Role of Serratia species in urinary tract infections. Arch Intern Med 1962; 109:536.</a></li><li><a class="nounderline abstract_t">Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004; 50:59.</a></li><li><a class="nounderline abstract_t">Chuang TY, Chuang CP, Cheng HH, Hsueh PR. Aortic valve infective endocarditis caused by Serratia liquefaciens. J Infect 2007; 54:e161.</a></li><li><a class="nounderline abstract_t">Yu VL. Serratia marcescens: historical perspective and clinical review. N Engl J Med 1979; 300:887.</a></li><li><a class="nounderline abstract_t">Mills J, Drew D. Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse. Ann Intern Med 1976; 84:29.</a></li><li><a class="nounderline abstract_t">Pegues DA, Shireley LA, Riddle CF, et al. Serratia marcescens surgical wound infection following breast reconstruction. Am J Med 1991; 91:173S.</a></li><li><a class="nounderline abstract_t">Sokalski SJ, Jewell MA, Asmus-Shillington AC, et al. An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Arch Intern Med 1992; 152:841.</a></li><li><a class="nounderline abstract_t">Fernández AL, Adrio B, Martínez Cereijo JM, et al. Clinical study of an outbreak of postoperative mediastinitis caused by Serratia marcescens in adult cardiac surgery. Interact Cardiovasc Thorac Surg 2020; 30:523.</a></li><li><a class="nounderline abstract_t">Rehman T, Moore TA, Seoane L. Serratia marcescens necrotizing fasciitis presenting as bilateral breast necrosis. J Clin Microbiol 2012; 50:3406.</a></li><li><a class="nounderline abstract_t">Vano-Galvan S, Álvarez-Twose I, Moreno-Martín P, Jaén P. Fulminant necrotizing fasciitis caused by Serratia marcescens in an immunosuppressed host. Int J Dermatol 2014; 53:e57.</a></li><li><a class="nounderline abstract_t">Prelog T, Jereb M, Cuček I, Jazbec J. Necrotizing fasciitis caused by Serratia marcescens after venous access port implantation in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2012; 34:e246.</a></li><li><a class="nounderline abstract_t">Aronson LC, Alderman SI. The Occurrence and Bacteriological Characteristics of S. marcescens from a Case of Meningitis. J Bacteriol 1943; 46:261.</a></li><li><a class="nounderline abstract_t">Cohen AL, Ridpath A, Noble-Wang J, et al. Outbreak of Serratia marcescens bloodstream and central nervous system infections after interventional pain management procedures. Clin J Pain 2008; 24:374.</a></li><li><a class="nounderline abstract_t">Civen R, Vugia DJ, Alexander R, et al. Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy. Clin Infect Dis 2006; 43:831.</a></li><li><a class="nounderline abstract_t">Dubouix A, Roques C, Segonds C, et al. Epidemiological investigation of a Serratia liquefaciens outbreak in a neurosurgery department. J Hosp Infect 2005; 60:8.</a></li><li><a class="nounderline abstract_t">Ariel I, Arad I, Soffer D. Autopsy findings of Serratia meningoencephalitis in infants. Pediatr Pathol 1986; 6:351.</a></li><li><a class="nounderline abstract_t">Campbell JR, Diacovo T, Baker CJ. Serratia marcescens meningitis in neonates. Pediatr Infect Dis J 1992; 11:881.</a></li><li><a class="nounderline abstract_t">Samonis G, Vouloumanou EK, Christofaki M, et al. Serratia infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis 2011; 30:653.</a></li><li><a class="nounderline abstract_t">Spernovasilis N, Maraki S, Kokorakis E, et al. Antimicrobial susceptibility of isolated pathogens from patients with contact lens-related bacterial keratitis in Crete, Greece: A ten-year analysis. Cont Lens Anterior Eye 2021; 44:101355.</a></li><li><a class="nounderline abstract_t">Badenoch PR, Thom AL, Coster DJ. Serratia ficaria endophthalmitis. J Clin Microbiol 2002; 40:1563.</a></li><li><a class="nounderline abstract_t">Das S, Sheorey H, Taylor HR, Vajpayee RB. Association between cultures of contact lens and corneal scraping in contact lens related microbial keratitis. Arch Ophthalmol 2007; 125:1182.</a></li><li><a class="nounderline abstract_t">Sridhar J, Kuriyan AE, Flynn HW Jr, et al. ENDOPHTHALMITIS CAUSED BY SERRATIA MARCESCENS: Clinical Features, Antibiotic Susceptibilities, and Treatment Outcomes. Retina 2015; 35:1095.</a></li><li><a class="nounderline abstract_t">Cheng KH, Leung SL, Hoekman HW, et al. Incidence of contact-lens-associated microbial keratitis and its related morbidity. Lancet 1999; 354:181.</a></li><li><a class="nounderline abstract_t">Mumcuoglu I, Kanyilmaz D, Yetkin MA, et al. Serratia marcescens bacteremia cases: A pseudo-outbreak experience. Am J Infect Control 2016; 44:852.</a></li><li><a class="nounderline abstract_t">Silva CV, Magalhães VD, Pereira CR, et al. Pseudo-outbreak of Pseudomonas aeruginosa and Serratia marcescens related to bronchoscopes. Infect Control Hosp Epidemiol 2003; 24:195.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. 32nd edition, CLSI, Wayne, PA 2022.</li><li class="breakAll">Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, USA, 2022.</li><li><a class="nounderline abstract_t">Ito R, Mustapha MM, Tomich AD, et al. Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene. mBio 2017; 8.</a></li><li><a class="nounderline abstract_t">Hanson ND, Sanders CC. Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae. Curr Pharm Des 1999; 5:881.</a></li><li class="breakAll">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0. Published on 3/31/2022. https://www.idsociety.org/practice-guideline/amr-guidance-2.0/#toc-9.</li><li><a class="nounderline abstract_t">Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009; 22:161.</a></li><li><a class="nounderline abstract_t">Kohlmann R, Bähr T, Gatermann SG. Effect of ampC derepression on cefepime MIC in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase. Clin Microbiol Infect 2019; 25:1158.e1.</a></li><li><a class="nounderline abstract_t">Sader HS, Castanheira M, Farrell DJ, et al. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagn Microbiol Infect Dis 2015; 83:389.</a></li><li><a class="nounderline abstract_t">Gaudereto JJ, Perdigão Neto LV, Leite GC, et al. Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Naumiuk L, Baraniak A, Gniadkowski M, et al. Molecular epidemiology of Serratia marcescens in two hospitals in Gdańsk, Poland, over a 5-year period. J Clin Microbiol 2004; 42:3108.</a></li><li><a class="nounderline abstract_t">Empel J, Baraniak A, Literacka E, et al. Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 2008; 52:2449.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Resistance Testing; 21st Informational Supplement. 2011; M100.</li><li><a class="nounderline abstract_t">Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440.</a></li><li><a class="nounderline abstract_t">Silva KE, Cayô R, Carvalhaes CG, et al. Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant Serratia marcescens Isolates from an Outbreak in a Brazilian Teaching Hospital. J Clin Microbiol 2015; 53:2324.</a></li><li><a class="nounderline abstract_t">Kazmierczak KM, Rabine S, Hackel M, et al. Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2016; 60:1067.</a></li><li><a class="nounderline abstract_t">Arana DM, Saez D, García-Hierro P, et al. Concurrent interspecies and clonal dissemination of OXA-48 carbapenemase. Clin Microbiol Infect 2015; 21:148.e1.</a></li><li><a class="nounderline abstract_t">Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008; 30:2040.</a></li><li><a class="nounderline abstract_t">Stewart AG, Paterson DL, Young B, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infect Dis 2021; 8:ofab387.</a></li><li><a class="nounderline abstract_t">Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC β-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:781.</a></li><li><a class="nounderline abstract_t">Harris PN, Wei JY, Shen AW, et al. Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother 2016; 71:296.</a></li><li><a class="nounderline abstract_t">Meini S, Tascini C, Cei M, et al. AmpC β-lactamase-producing Enterobacterales: what a clinician should know. Infection 2019; 47:363.</a></li><li><a class="nounderline abstract_t">Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC β-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 2012; 40:297.</a></li><li><a class="nounderline abstract_t">Choi SH, Kim YS, Chung JW, et al. Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use. Infect Control Hosp Epidemiol 2002; 23:740.</a></li><li><a class="nounderline abstract_t">Boyle RJ, Curtis N, Kelly N, et al. Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children. Pediatr Infect Dis J 2002; 21:935.</a></li><li><a class="nounderline abstract_t">Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 2002; 8:823.</a></li><li><a class="nounderline abstract_t">Livermore DM, Brown DF, Quinn JP, et al. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae? Clin Microbiol Infect 2004; 10:84.</a></li></ol></div><div id="topicVersionRevision">Topic 87709 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976608" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Serratia infections: from military experiments to current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976608" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serratia infections: from military experiments to current practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lettera di Bartolomeo Bizio al Chiarissimo canonico Angelo Bellani sopra il fenomeno della polenta porporina</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32393508" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Serratia marcescens Siderophore Serratiochelin Is Necessary for Full Virulence during Bloodstream Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24914224" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Serratia marcescens ShlA pore-forming toxin is responsible for early induction of autophagy in host cells and is transcriptionally regulated by RcsB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20713626" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : RssAB-FlhDC-ShlBA as a major pathogenesis pathway in Serratia marcescens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28366837" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : SlpE is a calcium-dependent cytotoxic metalloprotease associated with clinical isolates of Serratia marcescens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17960436" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36638403" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serratia Infection Epidemiology Among Very Preterm Infants in the Neonatal Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32699120" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Enterobacterales Infection after Intestinal Dominance in Hospitalized Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31413826" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serratia marcescens colonization in preterm neonates during their neonatal intensive care unit stay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27346925" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Marvelous but Morbid: Infective endocarditis due to Serratia marcescens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36968963" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidemiology and Clinical Outcomes of Non-HACEK Gram-Negative Infective Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16807859" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acquisition of multidrug-resistant Serratia marcescens by critically ill patients who consumed tap water during receipt of oral medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6108459" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antibiotic-sensitive Serratia marcescens infections complicating cardiopulmonary operations: contaminated disinfectant as a reservoir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27495382" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Serratia marcescens outbreak due to contaminated 2% aqueous chlorhexidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9350463" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Serratia marcescens outbreak associated with extrinsic contamination of 1% chlorxylenol soap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246120" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outbreak of Serratia marcescens in a neonatal intensive care unit: contaminated unmedicated liquid soap and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9569454" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Fatal reaction to transfusion of red-cell concentrate contaminated with Serratia liquefaciens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8073493" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Transfusion-transmitted Serratia liquifaciens from an autologous blood unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16584449" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal septic shock associated with transfusion-transmitted Serratia marcescens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791816" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Postoperative infections traced to contamination of an intravenous anesthetic, propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17682984" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822828" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11584257" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An outbreak of Serratia marcescens associated with the anesthetic agent propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24729502" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Outbreak of Serratia marcescens bloodstream infections in patients receiving parenteral nutrition prepared by a compounding pharmacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17080370" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Outbreak of Serratia marcescens colonization and infection traced to a healthcare worker with long-term carriage on the hands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10833342" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Epidemiology and susceptibility of serratia marcescens in a large general hospital over an 8-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9086167" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Postoperative Serratia marcescens wound infections traced to an out-of-hospital source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19783209" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Outbreaks of Serratia marcescens in neonatal and pediatric intensive care units: clinical aspects, risk factors and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511122" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Multifactorial origin of high incidence of Serratia marcescens in a cardio-thoracic ICU: analysis of risk factors and epidemiological characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392335" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Risk factors for acquisition of Serratia marcescens in a surgical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923282" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Microbiologic and clinical epidemiologic characteristics of the Chicago subset of a multistate outbreak of Serratia marcescens bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923282" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Microbiologic and clinical epidemiologic characteristics of the Chicago subset of a multistate outbreak of Serratia marcescens bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10755240" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20597676" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21174142" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31767041" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14461900" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Role of Serratia species in urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15380279" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17125840" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Aortic valve infective endocarditis caused by Serratia liquefaciens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/370597" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Serratia marcescens: historical perspective and clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1106290" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serratia marcescens endocarditis: a regional illness associated with intravenous drug abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928161" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Serratia marcescens surgical wound infection following breast reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558444" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31958124" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical study of an outbreak of postoperative mediastinitis caused by Serratia marcescens in adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22837315" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Serratia marcescens necrotizing fasciitis presenting as bilateral breast necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640271" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Fulminant necrotizing fasciitis caused by Serratia marcescens in an immunosuppressed host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22584779" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Necrotizing fasciitis caused by Serratia marcescens after venous access port implantation in a child with acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16560698" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Occurrence and Bacteriological Characteristics of S. marcescens from a Case of Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496300" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Outbreak of Serratia marcescens bloodstream and central nervous system infections after interventional pain management procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941362" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15823650" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Epidemiological investigation of a Serratia liquefaciens outbreak in a neurosurgery department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547373" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Autopsy findings of Serratia meningoencephalitis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1408491" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Serratia marcescens meningitis in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21222011" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Serratia infections in a general hospital: characteristics and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778366" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antimicrobial susceptibility of isolated pathogens from patients with contact lens-related bacterial keratitis in Crete, Greece: A ten-year analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923398" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Serratia ficaria endophthalmitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17846356" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Association between cultures of contact lens and corneal scraping in contact lens related microbial keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741815" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : ENDOPHTHALMITIS CAUSED BY SERRATIA MARCESCENS: Clinical Features, Antibiotic Susceptibilities, and Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421298" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Incidence of contact-lens-associated microbial keratitis and its related morbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27005589" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Serratia marcescens bacteremia cases: A pseudo-outbreak experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12683511" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pseudo-outbreak of Pseudomonas aeruginosa and Serratia marcescens related to bronchoscopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12683511" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pseudo-outbreak of Pseudomonas aeruginosa and Serratia marcescens related to bronchoscopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12683511" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pseudo-outbreak of Pseudomonas aeruginosa and Serratia marcescens related to bronchoscopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28851843" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Widespread Fosfomycin Resistance in Gram-Negative Bacteria Attributable to the Chromosomal fosA Gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10539994" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10539994" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Regulation of inducible AmpC beta-lactamase expression among Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136439" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : AmpC beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31128286" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of ampC derepression on cefepime MIC in Enterobacterales with chromosomally encoded inducible AmpCβ-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26162518" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30783003" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring Acinetobacter baumannii and Serratia marcescens Investigated Using Time-Kill and Disk Approximation Assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243068" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Molecular epidemiology of Serratia marcescens in two hospitals in Gdańsk, Poland, over a 5-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458126" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18458126" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Molecular survey of beta-lactamases conferring resistance to newer beta-lactams in Enterobacteriaceae isolates from Polish hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630334" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Carbapenemases: the versatile beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25878341" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant Serratia marcescens Isolates from an Outbreak in a Brazilian Teaching Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643349" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596781" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Concurrent interspecies and clonal dissemination of OXA-48 carbapenemase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19108792" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34395716" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpCβ-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23759352" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The use of cefepime for treating AmpCβ-lactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26542304" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30840201" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : AmpCβ-lactamase-producing Enterobacterales: what a clinician should know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22824371" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Antibiotic therapy for inducible AmpCβ-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517017" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Serratia bacteremia in a large university hospital: trends in antibiotic resistance during 10 years and implications for antibiotic use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12394816" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Clinical implications of inducible beta-lactamase activity in Gram-negative bacteremia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12519358" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706093" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
